# Treatment methods for acute lymphoblastic leukemia
The treatment of acute lymphoblastic leukemia (ALL) is intensive and is given in phases. The goal is first to bring the leukemia into remission (no detectable disease signs), then to prevent it from returning. The approach differs between children and adults, and depends heavily on biological characteristics of the leukemic cells (genetic abnormalities, immunophenotype) and personal factors such as age and overall health.
Induction therapy (first phase)
This is the intensive starting phase in which leukemic cells are destroyed as much as possible.
Chemotherapy combinations
ProveniIncluded in official guidelines, or approved by EMA or FDA
The standard treatment for children and many younger adults consists of a combination of multiple chemotherapy drugs, usually a block of three to four drugs at once: a corticosteroid (such as prednisone), vincristine, asparaginase and daunorubicin or idarubicin. These drugs work in different ways: some disrupt cell division, others determine the shape of DNA and make cells undergo apoptosis (self-destruction). The combination is more powerful than each drug alone.
Known side effects are infections (due to damage to white blood cells), anemia, thrombotic problems, nausea, vomiting, diarrhea, hair loss and damage to organs such as the heart, kidneys and nerves. The heart and nerves may suffer long-term effects. These side effects are usually supported: blood transfusions, anti-inflammatory drugs and antibiotics are given when needed. The induction phase usually lasts 4 to 6 weeks.
Steroids in combination
ProveniIncluded in official guidelines, or approved by EMA or FDA
For certain groups of patients (especially older adults or those with serious comorbidity) smaller chemotherapy combinations or steroids alone with other drugs are given. This is less intensive but also less effective; the choice depends on what someone can tolerate and the nature of the disease.
Targeted drug: BCR-ABL inhibitors (tyrosine kinase inhibitors)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Approximately 3 to 5% of adults and 5% of children with ALL have a Philadelphia chromosome (a defect in which two genes, BCR and ABL, are fused). This makes cells more aggressive. Tyrosine kinase inhibitors such as imatinib or dasatinib block the BCR-ABL protein and inhibit the growth of these cells. They are given from diagnosis, alongside chemotherapy.
Side effects include nausea, rash, fluid retention, muscle or joint pain and rarely serious heart problems. Regular heart monitoring is common.
---
Consolidation and intensification (second phase)
After induction, further blocks of chemotherapy follow to push back the disease even more strongly.
Further chemotherapy cycles
ProveniIncluded in official guidelines, or approved by EMA or FDA
Various intensive chemotherapy courses follow one another, usually with breaks of a few weeks between cycles. These contain partly the same drugs as induction, partly new ones (such as cytarabine, methotrexate or etoposide in higher doses). The aim is to eliminate all remaining leukemic cells without causing too much damage to the body.
Side effects are similar to induction: risk of infection, anemia, thrombotic problems, gastrointestinal problems and nerve damage. Prolonged bone marrow failure is possible; sufficient time for recovery between cycles is important.
Central nervous system (CNS) prophylaxis
ProveniIncluded in official guidelines, or approved by EMA or FDA
Leukemic cells can grow in the fluid around the brain and spinal cord and hide there from systemic chemotherapy. Therefore, many patients receive chemotherapy directly into the cerebrospinal fluid (intrathecal administration, usually methotrexate) and/or very high doses of chemotherapy by infusion that can cross the blood-brain barrier. This prevention of CNS disease is standard.
Side effects of intrathecal therapy can be headache, back pain, shortness of breath or (rarely) neurological complications. With very high doses of methotrexate, kidney damage or neurotoxicity can occur.
---
Maintenance phase (third phase)
This is long-term, less intensive, and serves to maintain remission. This phase usually lasts 2 to 3 years.
Maintenance chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Low-dose chemotherapy is given over a long time: usually daily mercaptopurine (oral) in combination with weekly methotrexate (oral or intravenous). This keeps the disease suppressed without continuously placing heavy burden on the body.
Side effects are less severe than in earlier phases, but can include nausea, fatigue, infections, and (rarely) liver abnormalities. Most patients can resume their normal life well during this phase.
---
Stem Cell Transplantation
Allogeneic stem cell transplantation (from donor)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For patients with high-risk ALL (certain genetic abnormalities, did not achieve complete remission, or ALL that has returned) allogeneic transplantation is an important part of treatment. The patient's bone marrow is first destroyed (conditioning), after which stem cells from a donor (usually family or unrelated donor) are injected.
The donor cells grow out and form a new immune system. This system can also attack remaining leukemia cells (graft-versus-leukemia effect). It is an intensive treatment: infections, organ damage, and graft-versus-host disease (GVHD, where donor cells attack the patient's body tissues) are common serious complications. Mortality from the transplantation itself occurs. But for high-risk patients this effort is often justified because the relapse risk is otherwise high.
ResearchediPositive results in clinical studies, not yet standard treatment
New conditioning regimens (such as low-dose regimens with fludarabine, thiotepa, and melphalan) are being investigated to reduce severity and mortality risk of transplantation, especially for elderly and vulnerable patients.
Autologous stem cell transplantation (own cells)
ResearchediPositive results in clinical studies, not yet standard treatment
In certain situations a patient's own stem cells can be harvested, multiplied, and returned after intensive chemotherapy. This is less risky than allogeneic because no GVHD occurs, but the graft-versus-leukemia effect is also absent. Use in ALL is limited and not standard.
---
Immune-targeted therapies
CAR-T-cell therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
CAR-T (chimeric antigen receptor T cell) is a revolutionary treatment for ALL. T cells from the patient are genetically modified so they carry a receptor that recognizes CD19 (a protein on B-cell leukemia cells). After multiplication these cells are returned. They recognize and kill leukemia cells.
CAR-T works especially well for B-cell ALL that no longer responds to chemotherapy. Many patients achieve long-term remission. Side effects include cytokine release syndrome (fever, blood pressure drop, organ damage) and immune effector cell-associated neurotoxicity (confusion, seizures). These are often serious and require ICU admission. Long-term immune function can become weak.
Currently many centers use CAR-T also in frontline (first-line) for patients with certain high-risk features.
Blinatumomab
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a bispecific antibody that binds simultaneously to leukemia cells (CD19) and to T cells (CD3), bringing them together. The T cells kill the leukemia cells. Blinatumomab is given as continuous intravenous infusion over several weeks.
It helps especially for patients in remission with minimal residual disease (MRD) detectable, or for recurrent disease. Side effects include neurological symptoms (tingling, confused thoughts), fever, infections, and allergic reactions. For patients who cannot tolerate chemotherapy well it is also used in earlier stages.
---
Treatment of relapse
Re-conditioning and renewed chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
When leukemia has returned, new chemotherapy combinations are tried, often more intensive than before. Many patients achieve a second remission. This is usually followed by stem cell transplantation.
CAR-T for relapse
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients whose ALL has returned after previous chemotherapy and sometimes transplantation have failed may benefit from CAR-T cell therapy. For many, this is a chance for sustained response, but success is lower than for first-line refractory or early relapse. Toxicity remains a point of concern, especially if the patient has already received substantial chemotherapy.
---
Experimental and research area
New tyrosine kinase inhibitors
ResearchediPositive results in clinical studies, not yet standard treatment
For Philadelphia chromosome-negative ALL with certain other genetic abnormalities (ABL-class compounds, RAS mutations), new inhibitors are being investigated (ponatinib, others). These can be given alone or with chemotherapy.
Venetoclax combinations
ResearchediPositive results in clinical studies, not yet standard treatment
Venetoclax is an agent that triggers apoptosis in cancer cells. In combination with vincristine, dexamethasone or hypomethylating agents, it is being investigated for elderly patients and for relapsed disease.
CRLF2- and TCF3-targeted therapies
ExperimentaliOngoing in study setting, outcome still unknown
Specific CAR-T cell constructs against CRLF2 (particularly relevant for Philadelphia-like leukaemia) and new approaches for TCF3-mutated leukaemia are in clinical trials.
Neoantigen-targeted immunotherapy
ExperimentaliOngoing in study setting, outcome still unknown
Customised T cells against patient-specific mutations in leukaemia cells are in the research phase. This is personalised medicine tailored to the individual.
Asparaginase combinations
ResearchediPositive results in clinical studies, not yet standard treatment
New combinations of asparaginase with other agents (for example, with EAAT1 inhibitors) are being investigated to increase efficacy and manage toxicity.
---
Supportive care
Infection control and blood transfusion
ProveniIncluded in official guidelines, or approved by EMA or FDA
Antibiotics, antivirals, antifungals and growth factors for white blood cells (G-CSF) are essential during intensive therapy. Blood transfusions and platelet concentrates maintain blood counts. Good nutritional management, dental care and strict hygiene prevent infections.
Organ function monitoring
ProveniIncluded in official guidelines, or approved by EMA or FDA
Cardiac, renal and pulmonary function are monitored regularly, especially with agents that pose a risk to these organs. Early detection of damage is crucial.
Psychosocial support
ProveniIncluded in official guidelines, or approved by EMA or FDA
Psychological support, social work, family counselling and pain management are essential parts of care, especially for prolonged treatment in children and adolescents. Medication adherence improves when support is good.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._